Pacira BioSciences, Inc.

Pacira BioSciences, Inc.

PCRXNYSE / NASDAQHealthcareSmall cap

$36.48$0.00 (0.0%)

Last close · Data as of Nov 18, 2026

Market cap
$892.0M
P/E
126.9x
EV / EBITDA
8.7x
Revenue
$726.4M
Net margin
1.0%
ROCE
3.0%

+49.6% over the last year

Pacira BioSciences, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 18 Nov 2026 close.

1M
+0.4%
3M
+52.0%
6M
+62.6%
1Y
+49.6%
5Y
-35.2%

52-week range

Day change $0.00 (0.0%) from $36 to $36 · Last close Nov 18, 2026

Best weekday to invest, historically

The same weekly amount in PCRX, bought on each weekday since 2021.

News & filings

What Pacira BioSciences filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating margin fell for three years, from 13.0% to 2.6%.

Strengths (1)

  • Free cash flow was more than five times net profit in fiscal 2025.

Prices to the 18 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

Read moreShow less

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Sector
Healthcare
Shares outstanding
41.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$892.0M
P/E
126.9x
P/B
1.3x
EV / EBITDA
8.7x
EV / Sales
1.5x
P/S
1.2x
52-week high
$36.49
52-week low
$19.16

Profitability

Operating margin
2.6%
Net margin
1.0%
EBITDA margin
16.9%
ROE
1.0%
ROCE
3.0%
ROA
0.6%
Asset turnover
0.57

Growth

Revenue
$726.4M
Revenue growth, 1Y
3.6%
Revenue CAGR, 3Y
2.9%
Net profit growth, 1Y
-107.1%
Free cash flow
$136.7M

Solvency

Current ratio
4.54
Debt / Equity
0.60
Debt / Assets
0.33
CFO / Net profit
21.62
Cash / Market cap
26.7%

Where the revenue went

Of every $100 of FY2025 revenue, $1 was left as net income.

Pacira BioSciences, Inc. income statement flow, FY2025
Pacira BioSciences, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$149.8M
RevenueGross profit$576.7M
Gross profitResearch and development$117.3M
Gross profitSelling, general and administrative$368.8M
Gross profitOther operating expenses$71.4M
Gross profitOperating income$19.2M
Operating incomePretax income$16.9M
Operating incomeInterest and other expense$2.3M
Pretax incomeTax and other$9.8M
Pretax incomeNet income$7.0M

Revenue and net profit

Revenue grew 3.6% in FY2025; net profit is the dashed line.

Pacira BioSciences, Inc. revenue and net profit by fiscal year
Pacira BioSciences, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$666.8M$15.9M
FY2023$675.0M$42.0M
FY2024$701.0M-$99.6M
FY2025$726.4M$7.0M

Cash flows

FY2025: $152.0M from operations, $136.7M free after investment (dashed).

Pacira BioSciences, Inc. operating and free cash flow by fiscal year
Pacira BioSciences, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$145.3M$115.2M
FY2023$154.6M$139.5M
FY2024$189.4M$178.8M
FY2025$152.0M$136.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$726.4M+3.6%1Y
EBITDA
$122.5M+320.7%1Y
Net profit
$7.0M
Cash from operations
$152.0M-19.7%1Y
Free cash flow
$136.7M-23.5%1Y
Revenue CAGR, 3Y
2.9%
Net profit CAGR, 3Y
-23.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$726.4M$122.5M$7.0M$136.7M1.0%+3.6%-107.1%

Monthly returns

Month-by-month returns of PCRX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.3B
Liabilities$571.8M
Equity$693.1M
Paid-in capital$1.1B
Retained earnings-$199.3M
Treasury stock$176.6M

Market cap against peers

8 peers: same sector, nearest by size.

  1. Pacira BioSciences, Inc. (this company)$892.0M

Peers map

Healthcare companies placed by value, growth and quality; PCRX highlighted.

P/E against peers

PCRX trades at 126.9x earnings against a peer median of -4.8x.

  1. Pacira BioSciences, Inc. (this company)126.9x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Annexon, Inc., Cullinan Therapeutics, Inc., Jade Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Pacira BioSciences, Inc.PCRXthis company$892.0M126.9x1.3x1.0%8.7x
ARS Pharmaceuticals, Inc.SPRY$900.7M-5.3x7.9x-149.9%-5.7x
Annexon, Inc.ANNX$892.9M-4.3x4.2x-97.7%-3.5x
Xencor, Inc.XNCR$890.4M—1.4x-14.5%—
Cullinan Therapeutics, Inc.CGEM$886.8M-4.0x2.2x-53.8%-3.3x
MeiraGTx Holdings plcMGTX$886.3M-7.8x-153.0x1971.4%-10.2x
Jade Biosciences, Inc.JBIO$875.6M—-18.7x-38.3%—
Certara, Inc.CERT$872.7M-547.2x0.8x-0.2%9.7x
Talkspace, Inc.TALK$871.1M111.8x7.4x6.7%129.1x
Peer median—-4.8x1.8x-26.4%-3.4x

Year-to-date ROI

PCRX since 1 January, against earlier years.

Historical volatility

PCRX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Pacira BioSciences, Inc. operating margin by fiscal year
Pacira BioSciences, Inc. operating margin by fiscal year
DateOperating margin
FY20229.0%
FY202313.0%
FY202412.8%
FY20252.6%
LineFY2025
Cost of revenueCost Of Revenue$149.8M
Gross profitGross Profit$576.7M
Operating expensesOperating Expense$557.5M
Research and developmentResearch And Development$117.3M
Other operating expensesOther Operating Expenses$14.1M
Depreciation and amortisationDepreciation And Amortization In Income Statement$57.3M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$57.3M
Amortization$57.3M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$57.3M
Total expensesTotal Expenses$707.2M
Pretax incomePretax Income$16.9M

Learn while you research

Academy chapters picked for Pacira BioSciences, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 126.9, learn when high multiples are justified.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →